Trametinib US PDUFA Date Extended to September 2013
Prescription Drug User Free Act goal for trametinib extended three months
GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for trametinib, its MEK inhibitor, has been extended by 3 months to 3 September 2013.
The company recently submitted additional manufacturing data to the Food and Drug Administration (FDA) and the extension to the original PDUFA goal date is to allow sufficient time for FDA to review the submission.
On 3 August 2012, GSK announced submission of a New Drug Application for trametinib as a treatment for patients with unresectable or metastatic melanoma with BRAF V600 mutations as detected by an FDA-approved test.
On 7 February 2013, GSK announced submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for trametinib monotherapy and in combination with dabrafenib as a treatment for patients with unresectable or metastatic melanoma with BRAF V600 mutations.
The new manufacturing information submitted to FDA will also be shared with the EMA according to the standard centralized review process.
All information on this site is provided “as-is” for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health.
More health news
Health NewsExperimental Drugs Battle Melanoma Nicely
Metastatic melanoma was treated with an experimental drug combination in clinical trials
Prescription DrugsDrug Application for Atrial Fibrillation
Eliquis submitted for review for the prevention of stroke and systemic embolism
Prescription DrugsFDA Advisory Committee Recommends Approval in US of Umeclidinium/Vilanterol
Anoro Ellipta to treat patients with COPD